Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)
Status:
Unknown status
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
The investigators will investigate whether dapagliflozin (FORXIGA) might improve lipoprotein
metabolism as well as hyperglycemia in Japanese patients with type II diabetes mellitus whose
HbA1c levels are less than 7.0% (from 20 to 65 years of age). The investigators will examine
changes of fasting lipoprotein profile including TG, TC, HDL-C, apoB-48 and RemL-C before and
after the 8 weeks administration of dapagliflozin.